文献速递乳腺癌

基于肿瘤细胞密度与浸润淋巴细胞(CelTIL)预测HER2阳性乳腺癌无化疗双靶向治疗病理缓解的模型

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
PubMed 文献 · Ann Oncol · 2018-01-01

PAMELA新辅助试验纳入151例HER2阳性乳腺癌患者,接受拉帕替尼联合曲妥珠单抗(HR阳性者加内分泌治疗)18周。治疗第15天(D15)的TILs与肿瘤细胞密度独立关联pCR,据此构建CelTIL评分;CelTIL低分与高分患者pCR率分别为0%与33%。该评分在LPT109096试验D15样本中得到验证。

要点

  • 治疗第15天TILs而非基线TILs独立关联pCR。
  • D15的TILs与肿瘤细胞密度均独立关联pCR。
  • CelTIL低分与高分患者pCR率分别为0%与33%。

核心结论

  • 治疗中(而非基线)TILs独立关联无化疗抗HER2治疗的疗效。
  • D15测量的TILs与肿瘤细胞密度联合评分提供独立预测信息。

研究设计与样本

  • PAMELA新辅助试验:151例HER2阳性乳腺癌患者接受拉帕替尼联合曲妥珠单抗(HR阳性者加内分泌治疗)18周。
  • 基线样本N=148,D15样本N=134;CelTIL在PAMELA中推导,并在LPT109096试验65例HER2阳性患者D15样本中验证。

主要发现

  • PAMELA中基线与D15 TILs在单变量分析中均显著关联pCR。
  • 多变量分析中D15 TILs(而非基线TILs)显著关联pCR。
  • D15时TILs与肿瘤细胞密度独立关联pCR,据此推导CelTIL。
  • D15 CelTIL作为连续变量显著关联pCR;CelTIL-low与CelTIL-high患者pCR率分别为0%与33%。
  • LPT109096中D15 CelTIL作为连续变量及按预设cut-off分组(75.0% vs 33.3%)均关联pCR。

关键数值与推荐

  • CelTIL-low患者pCR率0%,CelTIL-high患者pCR率33%。
  • LPT109096中按预设cut-off分组pCR率为75.0% vs 33.3%。

临床怎么用

  • D15的TILs与肿瘤细胞密度联合评分(CelTIL)可在新辅助抗HER2治疗完成时提供独立预测信息。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The presence of stromal tumor-infiltrating lymphocytes (TILs) is associated with increased pathologic complete response (pCR) and improved outcomes in HER2-positive early-breast cancer (BC) treated with anti-HER2-based chemotherapy. In the absence of chemotherapy, the association of TILs with pCR following anti-HER2 therapy-only is largely unknown. PATIENTS AND METHODS: The PAMELA neoadjuvant trial treated 151 women with HER2-positive BC with lapatinib and trastuzumab [and hormonal therapy if hormone receptor (HR)-positive] for 18 weeks. Percentage of TILs and tumor cellularity were determined at baseline (N = 148) and at day 15 (D15) of treatment (N = 134). Associations of TILs and tumor cellularity with pCR in the breast were evaluated. A combined score based on tumor cellularity and TILs (CelTIL) measured at D15 was derived in PAMELA, and validated in D15 samples from 65 patients with HER2-positive disease recruited in the LPT109096 neoadjuvant trial, where anti-HER2 therapy-only was administer for 2 weeks, then standard chemotherapy was added for 24 weeks. RESULTS: In PAMELA, baseline and D15 TILs were significantly associated with pCR in univariate analysis. In multivariable analysis, D15 TILs, but not baseline TILs, were significantly associated with pCR. At D15, TILs and tumor cellularity were found independently associated with pCR. A combined score (CelTIL) taking into account both variables was derived. CelTIL at D15 as a continuous variable was significantly associated with pCR, and patients with CelTIL-low and CelTIL-high scores had a pCR rate of 0% and 33%, respectively. In LPT109096, CelTIL at D15 was found associated with pCR both as a continuous variable and as group categories using a pre-defined cut-off (75.0% versus 33.3%). CONCLUSIONS: On-treatment TILs, but not baseline TILs, are independently associated with response following anti-HER2 therapy-only. A combined score of TILs and tumor cellularity measured at D15 provides independent predictive information upon completion of neoadjuvant anti-HER2-based therapy. CLINICAL TRIAL NUMBER: NCT01973660.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Nuciforo P, Pascual T, Cortés J, et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018. PMID: 29045543. doi:10.1093/annonc/mdx647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。